CD8A and neoplasm: Analysis of antigen-specific de novo T cell responses revealed significantly elevated numbers of CD8+ T cells specific for GPC3 epitope [31] in tumor-infiltrating lymphocytes from DEXP&A&N-treated mice than mice treated with DEXAFP and PBS (Fig. 4e).